Skip to main content

LA/LAA Clot Classification

 LA/LAA Clot Classification

Left Atrial (LA) and Left Atrial Appendage (LAA) Thrombus Classification

Introduction

Left atrial (LA) and left atrial appendage (LAA) thrombi are major sources of cardioembolic stroke, particularly in patients with Atrial Fibrillation, mitral valve disease, heart failure, and severe left atrial enlargement. Accurate characterization of thrombus morphology is important because thrombus size, mobility, and attachment influence embolic risk and procedural planning for cardioversion, catheter ablation, and LAA closure.

Although no universally accepted classification system exists, LA/LAA thrombi are commonly categorized according to morphology, mobility, location, and chronicity.


---

1. Classification by Morphology

Type I: Pedunculated (Mobile) Thrombus

Attached to the atrial wall or LAA by a narrow stalk.

Exhibits marked mobility during the cardiac cycle.

Highest embolic potential.

Can occasionally mimic an atrial myxoma.


Clinical significance: Immediate anticoagulation and postponement of elective procedures are usually required.


---

Type II: Sessile Thrombus

Broad-based attachment to the atrial wall or appendage.

Limited mobility.

Less likely to embolize than pedunculated thrombi.


Clinical significance: Still represents a contraindication to cardioversion or LAA intervention.


---

Type III: Ball Thrombus

Spherical, free-floating thrombus.

Usually found in massively enlarged left atria.

Most often associated with severe mitral stenosis.


Clinical significance: Extremely high embolic risk and may intermittently obstruct the mitral valve.


---

Type IV: Layered (Mural) Thrombus

Flat thrombus lining the wall of the LA or LAA.

Often difficult to detect.

May resemble spontaneous echo contrast.


Clinical significance: Frequently represents chronic thrombus formation.


---

2. Classification by Mobility

Mobile Thrombus

Moves independently from the atrial wall.

Higher embolic risk.

Commonly pedunculated.


Non-Mobile Thrombus

Fixed to the endocardial surface.

Lower immediate embolic risk.

More often chronic.



---

3. Classification by Location

A. LAA Thrombus

Most common location (>90% of thrombi in non-valvular AF).

Usually forms in the apex of the appendage.

Best visualized with transesophageal echocardiography (TEE).


B. Left Atrial Body Thrombus

More common in rheumatic mitral stenosis.

Associated with severe atrial enlargement and blood stasis.


C. Combined LA and LAA Thrombus

Extensive thrombotic burden involving both structures.

Indicates advanced thrombogenic substrate.



---

4. Classification by Chronicity

Fresh (Acute) Thrombus

Features:

Soft appearance

Less echogenic

Irregular borders

Greater mobility


Organized (Chronic) Thrombus

Features:

Dense echogenic appearance

Smooth contours

Reduced mobility

Frequently layered against the wall


Calcified Thrombus

Features:

Highly echogenic

Acoustic shadowing

Represents long-standing organized thrombus



---

Echocardiographic Description

When reporting LA/LAA thrombus on TEE, the following should be documented:

1. Location (LA body or LAA)


2. Size (length × width)


3. Mobility


4. Attachment site


5. Echogenicity


6. Presence of spontaneous echo contrast ("smoke")


7. LAA emptying velocity


8. Number of thrombi




---

Practical TEE Classification

A clinically useful TEE-based approach:

Grade Description

Grade 0 No thrombus
Grade 1 Small mural thrombus
Grade 2 Sessile thrombus occupying part of LAA
Grade 3 Large thrombus occupying most of LAA
Grade 4 Mobile or protruding thrombus extending toward LA cavity


Grades 3–4 are associated with the highest embolic risk.


---

Key Takeaways

Most LA thrombi originate in the LAA.

Mobile and pedunculated thrombi carry the greatest embolic risk.

Ball thrombus is rare but highly dangerous.

TEE remains the gold standard for thrombus characterization.

Thrombus morphology, mobility, and size should all be reported because they influence decisions regarding cardioversion, AF ablation, and LAA closure procedures.



Comments

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...